



Highlights FY2026 Outlook for FY2027



May 2026



NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国家药品监督管理局



Who is TruScreen

Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution




TruScreen Group Ltd is a revenue generating Life Science company with a unique, AI-enabled real-time cervical cancer screening device.

**FY26 annual sales exceeded NZD \$2.4m
- 42% YOY growth.**

TruScreen Group Ltd owns TruScreen Pty Ltd, the Australian operating company that manufactures and markets the TruScreen cervical cancer screening system.



The TruScreen Journey



TruScreen Sales Strategy



Device installations and SUS Sales


KEY FINANCIALS NZD (m)	FY 23 Actual	FY 24 Actual	FY25 Actual	FY26 Actual (unaudited)
Sales	1.66	2.1	1.7	2.4
Total Revenue	2.2	2.6	2.1	2.8
COGS	1.3	1.4	1.2	1.7
R&D	0.9	0.9	0.8	0.9
EBITDA	-2.4	-2.0	-2.2	-2.2
Write off of Non-Current Assets	-0.05	-	-	-
Amortisation & Depreciation	-	-	-	-
LOSS FOR YEAR	-2.4	-2.0	-2.2	-2.2
Net Assets	2.5	3.2	1.0	2.6
Cash	2.2	2.7	0.04	1.5

From FY25 to FY26:

- Sales increased 42% YOY
- SUS Sales increased 1% YOY
- Revenue increased 33% YOY
- EBITDA – no change YOY
- Net Assets increased 160% YOY
- China SUS/Device Pull Through -4% YOY


FY25 ACTUAL

NZ\$1.7m



FY26 ACTUAL

Unaudited sales NZ\$2.4m



Recurring Revenue Model

- **TruScreen manufactures two devices –**
 - **one made in China for use in China, where locally manufactured products have preferential market access**
 - **one made in Australia for other markets**
- **For each patient screened with the TruScreen device a new disposable Single Use Sensor (SUS) must be used. This creates a recurring revenue model with a consumable sale for each patient screened with TruScreen.**

TruScreen Sales Strategy

- Whilst many other medical technology companies seek to commercialize their devices in developed countries, TruScreen focuses on Low and Middle Income Countries (LMICs) such as China, Mexico, Vietnam, India, Indonesia and Zimbabwe.
- Working with global and national NGOs, to manage large scale public health screening programs
- These countries and other LMICs have no or minimal large-scale cervical cancer screening programs and infrastructure. This creates a gap in the market for TruScreen that is not available in the developed markets and allows quicker market access from a relative lack of existing competition.
- In comparison with cytology and HPV DNA screening TruScreen is ‘capital light’, not requiring lab infrastructure to be established prior to commencing screening.

TruScreen Regulatory Approvals

Recognized by

- World Health Organisation (WHO)
- UNITAID
- Clinton Health Access Initiative
- Daffodil Foundation - Australia
- China Obstetricians and Gynaecologists Association
- China Society for Colposcopy and Cervical Pathology
- Russia Cervical Cancer Screening Guideline
- Vietnam Hospital Technical List


International Approvals:

- CE Mark, European Union
- NMPA, China
- TGA, Australia
- MHRA, UK
- SFDA, Saudi Arabia
- Roszdravnadzor, Russia
- COFEPRIS, Mexico
- WAND New Zealand
- Zimbabwe Ministry of Health
- IEAKI Indonesia
- Vietnam MOH
- India (Test Licence)
- Uzbekistan
- HSA, Singapore
- Thai FDA

International Quality Accreditation:

- ISO 13485
- IEC 60601-1
- IEC 60601-1-2
- CE Mark

Global presence



TruScreen Highlights FY 2026



FY2026 Highlights — Five Marquee Wins

01 260,000-woman Vietnam programme

5-year cervical cancer screening programme launched in Ho Chi Minh City with HPHA & Gorton Health Services. Planned national expansion in a market of 35M women of screening age.

02 India re-entry

Renovate Biologicals Pvt Ltd appointed as distributor. Interim product testing licence (Jul-25), 10 devices shipped. Full regulatory submission Apr-26.

03 BMC Cancer landmark study

14,982 women, 64 hospitals, 9 provinces. CIN2+ sensitivity 87%, CIN3+ sensitivity 90%. Largest opto-electronic cervical screening study ever published.

04 UNITAID — 3 proposals submitted

14 high-burden countries, 1Bn women addressable market, up to US\$18.4m potential revenue as consortium lead.

05 Distributor footprint expanded

New distributors signed in South Africa, Uzbekistan, Bangladesh, Romania and Italy. Pending in Nigeria, Rwanda and Palestine.

A Diversified Global Footprint

Active markets

- China (61.3% of FY26 sales)
- Vietnam (4 public hospitals + private)
- Zimbabwe (national expansion)
- Mexico (lab-system entry)
- Central Asia / Russia (multi-centre)

Launching FY27

- India (regulatory approval pending)
- Indonesia (POGI launch · July 2026)
- Singapore · Thailand · Malaysia
- Bangladesh (Xerox Medica)
- Kazakhstan (commercial use early FY27)

Pipeline / new signings

- South Africa (AIR · pilot study)
- Uzbekistan (Albatros Health Care)
- Romania · Italy (signed)
- Nigeria (LASUTH · Gates Foundation app.)
- Rwanda · Sri Lanka · Palestine (in negotiations)

China — The Anchor Market

61.3%

of FY2026 product sales

Consumable sales volumes met expectations despite challenging economic conditions.

Anticipated guideline integration into:

- CSCCP guidelines update
- COGA Blue Book — 2nd edition (2026)
- Expert Consensus on opto-electronic screening

Landmark BMC Cancer publication · Feb 2026

14,982

women

64

hospitals

9

provinces

Clinical performance vs Liquid-Based Cytology & hrHPV

87%

CIN2+ sensitivity

90%

CIN3+ sensitivity

0.72

AUC for CIN2+

"TruScreen has the highest AUC for both CIN2+ and CIN3+, indicating it was the most accurate test overall." — Study authors, BMC Cancer (2026)



Vietnam & Indonesia — South-East Asia Growth Engine

Vietnam

260,000

women to be screened in Ho Chi Minh City over 5 years (with HPHA & Gorton Health Services)

- Adopted by 4 leading public hospitals in South Vietnam.
- Private-sector entry: 1 hospital integrated into daily clinic; 4 awaiting approval; 3 more preparing applications.
- Planned national expansion — Vietnam has ~35M women of screening age.
- Foundation for broader public-sector hospital acceptance now established.

Indonesia

95M

women of screening age — government-funded mass screening program creates enormous opportunity

- Pilot clinical study underway with Marwa Mitra Medika.
- Results to be presented at POGI Annual Scientific Meeting — July 2026.
- TruScreen & distributor sponsoring the conference and product launch symposium.
- Collaboration planned with Ministry of Health for inclusion in public screening programmes.

India Re-Entry & South-East Asia Regulatory Progress

India

468M

women of screening age

Renovate Biologicals Pvt Ltd appointed distributor (Apr-25). Interim product testing licence (Jul-25) — 10 devices shipped. Regulatory submission filed Apr-26, approval expected within 3-6 months. Consortium of private hospitals lined up to adopt TruScreen subject to approval.

Regulatory & market-entry milestones — South-East Asia

● India ● South-East Asia



SE Asia reference centre established with Dr. S. C. Quek at Parkway Gynaecology Screening & Treatment Centre, Gleneagles Hospital, Singapore.



Africa — Three Growth Stories

Zimbabwe

20,000

screenings planned in CY2026

Re-validation by the National Microbiology Reference Lab (Aug-25) led the Ministry of Health to approve TruScreen as a primary screening test where HPV DNA testing is unavailable, and as a confirmatory test for HPV-positive women nationwide. 30,000+ women already screened since 2022 with the National AIDS Council.

South Africa

Jul 26

SAHPRA approval expected

New distributor AIR appointed (Nov-25). Product registration with the South African Health Products Regulatory Authority submitted Mar-26. A pilot clinical study has been planned to commence on receipt of regulatory approval, supporting market entry.

Nigeria

Gates

Foundation grant application

Collaboration with LASUTH and LASUCOM on a Bill & Melinda Gates Foundation grant application, TruScreen selected as the cornerstone device. First African clinical reference centre to be established with Prof. Chibuiké Chigbu, University of Nigeria Teaching Hospital. NGO partnerships with SCIDaR and RedAid.

Central Asia, LatAm & New Distributors

Uzbekistan

NZD 1.26m

30-mo revenue potential through CY2028

Albatros Health Care LLC appointed (May-26) a leading medical device distributor. Pilot clinical study commencing June 2026 with ethics approval, led by a senior government medical advisor.

Central Asia

2,000

women in multi-centre study

IMSystem multi-centre clinical study to secure recognition as a primary screening method in government healthcare. Kazakhstan to commence commercial use early FY27. Kyrgyzstan & Belarus registrations expected Q3 FY27.

Mexico

FY27

sales expected to commence

Distributor Sunbird ran social media and digital campaigns and established online training centres. Now entering the laboratory system and in discussions with major laboratory chains.

Bangladesh

NZD 554k

projected first-year sales

New distributor Xerox Medica Limited appointed (May-26). Government procurement application to be submitted June 2026 to meet the budget deadline.

UNITAID — A Step-Change Opportunity

14

high-burden countries
across Africa, Asia-Pacific & LatAm

1Bn

addressable screening-age
women across target geographies

US\$18.4m

potential revenue to TruScreen
as consortium lead

Why TruScreen fits the UNITAID brief

- Point-of-care, portable AI technology — purpose-built for low-resource settings where laboratories, pathologists and patient recall are unavailable.
- Primary screening where labs are absent · HPV triage where HPV (incl. Dalton Bio) is primary · same-visit complement in screen-and-treat settings.
- Complementary, not competitive, to HPV-DNA expansion under the WHO 90-70-90 elimination strategy.

Track record: 30,000+ women already screened in Zimbabwe since 2022 with the National AIDS Council · regulatory approvals across all 14 target countries.

Clinical & Scientific Milestones

Jan 2025

WHO AI Collaboration

TruScreen invited to present at WHO Global AI Collaboration Meeting on cervical cancer screening.

May 2025

Saudi Arabia study

Published Saudi Arabia study confirms TruScreen sensitivity and specificity vs. pap smear.

Jan 2026

Pregnancy safety

Clinical study validates TruScreen efficacy and safety for pregnant women — broadens use cases.

Feb 2026

BMC Cancer landmark

World's largest opto-electronic study — 14,982 women, 64 hospitals. CIN2+ 87%, CIN3+ 90%, AUC 0.72.

Mar 2026

Sichuan University

297-patient study shows TruScreen + hr-HPV co-testing is superior to either modality alone.

Through 2026

30+ trials cumulative

TruScreen now backed by 30+ peer-reviewed studies covering 40,000+ women across 20+ countries.

Commercial & Distributor Expansion

Asia-Pacific

Jan 2025
Indonesia distributor appointed (95M women).

Apr 2025
India re-entry — Renovate Biologicals Pvt Ltd.

Apr 2025
Vietnam — 260,000-woman public programme launches in HCMC.

May 2025
Dalton Bio HPV distribution rights for India.

Aug 2025
Public screening — Northeast India.

May 2026
Uzbekistan distributor formally appointed.

Africa & Middle East

Nov 2025
South Africa — AIR Group appointed as distributor.

Mar 2026
South Africa — SAHPRA registration submission filed.

May 2026
Nigeria — LASUTH / Gates Foundation grant submitted.

Dec 2025
Western Europe & Middle East commercial scoping.

Pipeline & Studies

Feb 2025
MOU with Hangzhou Dalton Bioscience.

Aug 2025
Public screening programme — Uzbekistan.

2026
New distributors signed in Romania and Italy.

2026
Pending in Rwanda, Sri Lanka, Palestine, Bangladesh.

TruScreen Outlook: FY2027 & Growth Strategies



What's Coming Next

FY2027 outlook

- **India** Full regulatory approval expected within 3–6 months of Apr-26 filing.
- **South Africa** SAHPRA approval expected Jul 2026; pilot study to follow.
- **Indonesia** Commercial use targeted in FY27.
- **Uzbekistan** Scale-up under new distributor + public programme.
- **UNITAID** Funding decisions on three proposals through CY2026.
- **Margin** Country mix expected to lift gross margin above FY26's 31.5%.

Catalyst Drivers

- H2 CY2026** India regulatory approval; first commercial shipments.
- H2 CY2026** South Africa SAHPRA approval and pilot study start.
- H2 CY2026** UNITAID consortium decisions.
- H2 CY2026** Indonesia / ME market activation.
- CY2026** Nigeria — first African clinical reference centre opens.
- CY2027** Vietnam — national expansion beyond HCMC.

Growth Strategies



Market expansion to continue with China the key focus



Focus on key growth provinces (Shandong, Jiangsu,, Hunan, Zhejiang, Guangdong, Guangxi) - Total population 496m



Enter huge African market collaborating with NGOs



Strengthen vertical Asian market from Indonesia through China, and capitalise on Indian distribution network



Target Govt and NGO funded programs in Zimbabwe, Vietnam, Mexico and Uzbekistan



Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA , CSCCP) to build acceptance and remove barriers to sale



Focus on countries with limited or nil cervical screening capability



Developing strategic partnerships for complementary woman's health services



Capitalise on global focus on AI enabled cervical cancer technologies – e.g. WHO



Expand product portfolio to include Dalton Bio HPV related IVD products, including HPV DNA tests and self sampling



Reduce SUS and Device COGS and increase margins

The Game Changer

1

The timeline compression of WHO's 90-70-90 milestones¹ to December 2030 - Sense of Urgency




2

UNITAID and global NGOs funding by late 2026 to drive cervical cancer screening



¹ <https://www.who.int/initiatives/cervical-cancer-elimination-initiative>

TruScreen Market Potential



DaltonBio Strategic Alliance


- **Q4 FY25** - Memorandum of Understanding signed with Dalton Biosciences (DaltonBio)
- **Q1 FY26** - TruScreen and Dalton Bio sign Distribution Agreement for HPV products in India



1. TruScreen to be appointed a global distributor of DaltonBio HPV related IVD products (excluding U.S.A. and Canada).
2. DaltonBio to explore opportunities to assist sales of TruScreen's AI enabled real time cervical screening device within its distribution network, notably in its selected distributors in China and South America. DaltonBio have 200 sub distributors in China which may augment TruScreen's current distribution network in it's largest market.

The collaboration will enhance access to innovative cervical cancer screening and detection solutions by leveraging the technology strengths of both companies. As demonstrated in the COGA landmark study (2023) and Beijing Obstetrics and Gynecology Hospital study (Dovepress, May 2025), co-testing improved TruScreen's already impressive standalone sensitivity significantly.

Thank you.




Tony Ho
Executive Chairman

E – tonyho@truscreen.com

TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia

www.truscreen.com



Guy Robertson
Chief Financial Officer

E – guyrobertson@truscreen.com



Disclaimer

This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company. This presentation should be read in conjunction with the Company’s annual report, market releases and other periodic and continuous disclosure announcements, which are available at www.nzx.com. This presentation does not constitute an offer, advertisement or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer, advertisement or invitation.

Not financial product advice

This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire the Company’s securities, and has been prepared without taking into account the objectives, financial situation or needs of prospective investors. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and consult a financial adviser, solicitor, accountant or other professional adviser if necessary.

Past performance

Any past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. No representations or warranties are made as to the accuracy or completeness of such information.

Future performance

This presentation includes certain “forward-looking statements” about the Company and the environment in which the Company operates. Forward-looking information is inherently uncertain and subject to contingencies, known and unknown risks and uncertainties and other factors, many of which are outside of the Company’s control, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. A number of important factors could cause actual results or performance to differ materially from any forward-looking statements. No assurance can be given that actual outcomes or performance will not materially differ from the forward-looking statements. The forward-looking statements are based on information available to the Company as at the date of this presentation. Except as required by law or regulation (including the Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.